MolDX: Molecular Biomarker Testing for Risk Stratification of Cutaneous Squamous Cell Carcinoma

This contractor does not cover current molecular biomarker tests used to risk stratify individuals with cutaneous squamous cell carcinoma (cSCC). The policy provides no covered indications, nor does it specify documentation, prior authorization, or frequency limits for these tests.

"Molecular biomarker tests used to risk stratify individuals with cutaneous squamous cell carcinoma (cSCC) are non-covered by this contractor."

Sign up to see full coverage criteria, indications, and limitations.